Broad Genomic Testing in NSCLC: No Survival Benefit?
A retrospective analysis of patients with advanced non-small cell lung cancer treated in community clinics found no benefit of broad genomic testing over routine testing for abnormalities in EGFR and ALK However, the reason may have more to do with patients not receiving targeted therapy than with any inherent flaws in genomics-guided precision medicine.